Compare Procter & Gamble Health with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs CIPLA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH CIPLA PROCTER & GAMBLE HEALTH/
CIPLA
 
P/E (TTM) x 47.1 38.0 124.1% View Chart
P/BV x 5.0 3.9 128.6% View Chart
Dividend Yield % 9.4 0.4 2,289.4%  

Financials

 PROCTER & GAMBLE HEALTH   CIPLA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
CIPLA
Mar-19
PROCTER & GAMBLE HEALTH/
CIPLA
5-Yr Chart
Click to enlarge
High Rs3,549678 523.5%   
Low Rs1,301484 269.0%   
Sales per share (Unadj.) Rs511.4198.2 258.0%  
Earnings per share (Unadj.) Rs61.318.5 330.9%  
Cash flow per share (Unadj.) Rs74.035.0 211.6%  
Dividends per share (Unadj.) Rs440.003.00 14,666.7%  
Dividend yield (eoy) %18.10.5 3,513.1%  
Book value per share (Unadj.) Rs927.8186.3 497.9%  
Shares outstanding (eoy) m16.60805.70 2.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.72.9 161.8%   
Avg P/E ratio x39.631.4 126.2%  
P/CF ratio (eoy) x32.816.6 197.3%  
Price / Book Value ratio x2.63.1 83.8%  
Dividend payout %717.916.2 4,432.7%   
Avg Mkt Cap Rs m40,257468,031 8.6%   
No. of employees `0001.122.6 5.0%   
Total wages/salary Rs m1,31328,565 4.6%   
Avg. sales/employee Rs Th7,486.77,053.1 106.1%   
Avg. wages/employee Rs Th1,157.61,261.5 91.8%   
Avg. net profit/employee Rs Th897.2659.1 136.1%   
INCOME DATA
Net Sales Rs m8,490159,710 5.3%  
Other income Rs m2444,766 5.1%   
Total revenues Rs m8,734164,475 5.3%   
Gross profit Rs m1,48230,973 4.8%  
Depreciation Rs m21113,263 1.6%   
Interest Rs m01,684 0.0%   
Profit before tax Rs m1,51420,791 7.3%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5635,695 9.9%   
Profit after tax Rs m1,01714,924 6.8%  
Gross profit margin %17.519.4 90.0%  
Effective tax rate %37.127.4 135.6%   
Net profit margin %12.09.3 128.2%  
BALANCE SHEET DATA
Current assets Rs m15,343124,266 12.3%   
Current liabilities Rs m1,96037,715 5.2%   
Net working cap to sales %157.654.2 290.9%  
Current ratio x7.83.3 237.6%  
Inventory Days Days4991 53.8%  
Debtors Days Days2895 30.0%  
Net fixed assets Rs m1,209105,190 1.1%   
Share capital Rs m1661,611 10.3%   
"Free" reserves Rs m15,235148,511 10.3%   
Net worth Rs m15,401150,123 10.3%   
Long term debt Rs m038,301 0.0%   
Total assets Rs m17,595239,633 7.3%  
Interest coverage xNM13.3-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.50.7 72.4%   
Return on assets %5.86.9 83.4%  
Return on equity %6.69.9 66.4%  
Return on capital %10.311.8 86.7%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63657,410 2.9%   
Fx outflow Rs m4,36819,041 22.9%   
Net fx Rs m-2,73238,368 -7.1%   
CASH FLOW
From Operations Rs m-1,30416,911 -7.7%  
From Investments Rs m12,697-16,687 -76.1%  
From Financial Activity Rs m-301-3,487 8.6%  
Net Cashflow Rs m11,093-3,451 -321.4%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 51.8 20.8 249.0%  
Indian inst/Mut Fund % 18.2 12.2 149.2%  
FIIs % 1.0 23.7 4.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 29.1 26.2 111.1%  
Shareholders   28,591 161,166 17.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

PROCTER & GAMBLE HEALTH Share Price Up by 7%; BSE HEALTHCARE Index Down 0.3% (Market Updates)

Aug 7, 2020 | Updated on Aug 7, 2020

PROCTER & GAMBLE HEALTH share price is trading up by 7% and its current market price is Rs 4,703. The BSE HEALTHCARE is down by 0.3%. The top gainers in the BSE HEALTHCARE Index is PROCTER & GAMBLE HEALTH (up 6.9%). The top losers are DR. REDDYS LAB and STRIDES PHARMA SCIENCE (down 0.1%).

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

Elon Musk Gives Us a Trading Opportunity(Fast Profits Daily)

Jul 28, 2020

Elon Musk made a statement recently which I believe, gives us a fast profit trading opportunity.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Aug 7, 2020 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS